319 related articles for article (PubMed ID: 33820450)
21. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.
Li Q; Li J; Cai Y; Zou Y; Chen B; Zou F; Mo J; Han T; Guo W; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Aug; 28(15):115601. PubMed ID: 32631570
[TBL] [Abstract][Full Text] [Related]
23. Identification of a Series of
Harrison LA; Atkinson SJ; Bassil A; Chung CW; Grandi P; Gray JRJ; Levernier E; Lewis A; Lugo D; Messenger C; Michon AM; Mitchell DJ; Preston A; Prinjha RK; Rioja I; Seal JT; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
J Med Chem; 2021 Aug; 64(15):10742-10771. PubMed ID: 34232650
[TBL] [Abstract][Full Text] [Related]
24. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
25. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
[TBL] [Abstract][Full Text] [Related]
26. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
[TBL] [Abstract][Full Text] [Related]
27. A 7-methoxybicoumarin derivative selectively inhibits BRD4 BD2 for anti-melanoma therapy.
Yang GJ; Wang W; Lei PM; Leung CH; Ma DL
Int J Biol Macromol; 2020 Dec; 164():3204-3220. PubMed ID: 32860796
[TBL] [Abstract][Full Text] [Related]
28. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
[TBL] [Abstract][Full Text] [Related]
29. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
[TBL] [Abstract][Full Text] [Related]
30. Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Chen J; Li Y; Zhang J; Zhang M; Wei A; Liu H; Xie Z; Ren W; Duan W; Zhang Z; Shen A; Hu Y
Eur J Med Chem; 2021 Jan; 209():112868. PubMed ID: 33077265
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of novel 4,4-difluoro-1-methyl-N, 6-diphenyl-5, 6-dihydro-4H-pyrimido [4, 5-b] [1, 2, 4] triazolo [4, 3-d] [1, 4] diazepin-8-amine derivatives as potential BRD4 inhibitors.
Li J; Zhang W; Qiu Q; Zhou D; Feng Z; Tong Z; Wei J; Huang W; Li J; Qian H; Shi W
Chem Biol Drug Des; 2021 May; 97(5):1117-1128. PubMed ID: 33638254
[TBL] [Abstract][Full Text] [Related]
32. An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells.
Yang GJ; Song YQ; Wang W; Han QB; Ma DL; Leung CH
Bioorg Chem; 2021 Sep; 114():105158. PubMed ID: 34378541
[TBL] [Abstract][Full Text] [Related]
33. Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study.
Kim JH; Pandit N; Yoo M; Park TH; Choi JU; Park CH; Jung KY; Lee BI
Sci Rep; 2023 Jul; 13(1):10805. PubMed ID: 37402749
[TBL] [Abstract][Full Text] [Related]
34. Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site.
Liu Z; Li Y; Chen H; Lai HT; Wang P; Wu SY; Wold EA; Leonard PG; Joseph S; Hu H; Chiang CM; Brasier AR; Tian B; Zhou J
J Med Chem; 2022 Feb; 65(3):2388-2408. PubMed ID: 34982556
[TBL] [Abstract][Full Text] [Related]
35. Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.
Liu Z; Chen H; Wang P; Li Y; Wold EA; Leonard PG; Joseph S; Brasier AR; Tian B; Zhou J
J Med Chem; 2020 May; 63(10):5242-5256. PubMed ID: 32255647
[TBL] [Abstract][Full Text] [Related]
36. Cell-based protein stabilization assays for the detection of interactions between small-molecule inhibitors and BRD4.
Schulze J; Moosmayer D; Weiske J; Fernández-Montalván A; Herbst C; Jung M; Haendler B; Bader B
J Biomol Screen; 2015 Feb; 20(2):180-9. PubMed ID: 25266565
[TBL] [Abstract][Full Text] [Related]
37. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
Zhao L; Wang Y; Cao D; Chen T; Wang Q; Li Y; Xu Y; Zhang N; Wang X; Chen D; Chen L; Chen YL; Xia G; Shi Z; Liu YC; Lin Y; Miao Z; Shen J; Xiong B
J Med Chem; 2015 Feb; 58(3):1281-97. PubMed ID: 25559428
[TBL] [Abstract][Full Text] [Related]
38. Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC).
Li Z; Ma S; Yang X; Zhang L; Liang D; Dong G; Du L; Lv Z; Li M
Eur J Med Chem; 2021 Oct; 222():113608. PubMed ID: 34119833
[TBL] [Abstract][Full Text] [Related]
39. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
40. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
